People with type 2 diabetes (T2D) on basal insulin, starting continuous glucose monitoring (CGM) had a 44% lower risk of dying from any cause after one year compared with those who did not use CGM, with the risk being 35% lower after two years, according to an analysis of patient data being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

People with type 2 diabetes (T2D) on basal insulin, starting continuous glucose monitoring (CGM) had a 44% lower risk of dying from any cause after one year compared with those who did not use CGM, with the risk being 35% lower after two years, according to an analysis of patient data being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

People with type 2 diabetes (T2D) who began using continuous glucose monitoring (CGM) while receiving basal insulin had a 44% lower risk of dying from any cause after one year than those who did not use ...